Neumora (NMRA) Q2 Loss Improves 10%

Neumora Therapeutics (NASDAQ:NMRA), a clinical-stage neuroscience company developing targeted therapies for brain diseases, released its second quarter 2025 results on August 6, 2025. The most significant news was a reduction in both research and development spending and overall net loss, while the company advanced multiple programs in its clinical pipeline. Neumora reported a net loss per share of $(0.33), an improvement from $(0.37) the prior year. Overall, the period reflected careful financial management and steady pipeline progress, but continued high cash usage and dependence on future clinical outcomes. Source: Analyst estimates for the quarter provided by FactSet. Neumora Therapeutics is focused on discovering, developing, and commercializing therapies for brain diseases using a precision neuroscience approach. Its programs target high-prevalence conditions such as major depressive disorder (MDD), agitation in Alzheimer’s disease, schizophrenia, and obesity. Instead of a one-size-fits-all model, it uses advanced data science and artificial intelligence to pinpoint and monitor patient subgroups for better trial outcomes and future treatment matching.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool